S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
NYSE:BHC

Bausch Health Companies (BHC) Stock Forecast, Price & News

$8.23
+0.03 (+0.37%)
(As of 06/2/2023 ET)
Compare
Today's Range
$8.09
▼
$8.38
50-Day Range
$5.72
▼
$8.80
52-Week Range
$4.00
▼
$10.23
Volume
2.13 million shs
Average Volume
4.57 million shs
Market Capitalization
$2.98 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.88
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Bausch Health Companies MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
7.8% Upside
$8.88 Price Target
Short Interest
Bearish
6.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
1.29mentions of Bausch Health Companies in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
11.99%
From $3.17 to $3.55 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

655th out of 983 stocks

Pharmaceutical Preparations Industry

327th out of 486 stocks

See Top Rated MarketRank™ Stocks Here

BHC stock logo

About Bausch Health Companies (NYSE:BHC) Stock

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refer to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologics, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Receive BHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.

BHC Stock News Headlines

May 18, 2023 | marketbeat.com
Zoetis Declares New Dividend, Hinting At Undervaluation (BHC)
Zoetis shareholders woke up to news of JAB's acquisition of Pumpkin, a per insurance platform where Zoetis owns a minority stake. 2023 outlooks suggest a rally
May 31, 2023 | finance.yahoo.com
OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease
June 2, 2023 | Vantage Point (Ad)
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
May 29, 2023 | ca.finance.yahoo.com
Bausch Health: Prescription for Profits or Risky Business?
May 22, 2023 | americanbankingnews.com
Bausch Health Companies (NYSE:BHC) Price Target Raised to $9.50
May 20, 2023 | americanbankingnews.com
StockNews.com Begins Coverage on Bausch Health Companies (NYSE:BHC)
May 20, 2023 | americanbankingnews.com
Bausch Health Companies (NYSE:BHC) Trading Up 6.6%
May 20, 2023 | americanbankingnews.com
Bausch Health Companies Sees Unusually Large Options Volume (NYSE:BHC)
June 2, 2023 | Vantage Point (Ad)
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
May 19, 2023 | finance.yahoo.com
15 Best Stocks to Buy and Hold According to Billionaire Carl Icahn
May 18, 2023 | finance.yahoo.com
Bausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich
May 18, 2023 | msn.com
Bausch Health Options Traders: Stock Will Remain Below This Level Through July Expiration
May 18, 2023 | finance.yahoo.com
New Clinical Study Suggests the Use of OraPharma’s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis
May 18, 2023 | finance.yahoo.com
The 6.3% return this week takes Bausch + Lomb's (NYSE:BLCO) shareholders one-year gains to 18%
May 18, 2023 | msn.com
Why Bausch Health Shares Soared Over 24% Today
May 17, 2023 | msn.com
Bausch Health stock soars after company says rival application for generic version of its IBS drug can’t be approved until 2029
May 17, 2023 | finance.yahoo.com
U.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
May 17, 2023 | finance.yahoo.com
Why Shares of Bausch Health Soared Wednesday
May 14, 2023 | americanbankingnews.com
Traders Buy Large Volume of Bausch Health Companies Put Options (NYSE:BHC)
May 10, 2023 | seekingalpha.com
Bausch Health: Bullish On Long-Term Prospects, Awaiting Subsiding Headwinds
May 10, 2023 | americanbankingnews.com
Bausch Health Companies (NYSE:BHC) and Biophytis (NASDAQ:BPTS) Head to Head Review
May 9, 2023 | seekingalpha.com
Bausch Health: There's Still Uncertainty
May 8, 2023 | finanznachrichten.de
Bausch Health Companies Inc.: Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week 2023
May 8, 2023 | finance.yahoo.com
Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023
May 4, 2023 | msn.com
Bausch Health stock falls ~15% as Q1 net loss widens amid revenue miss
May 4, 2023 | cnbc.com
Bausch Health's quarter disappoints, guidance beats. But uncertainty prevails over patent litigation
May 4, 2023 | americanbankingnews.com
StockNews.com Downgrades Bausch Health Companies (NYSE:BHC) to Hold
See More Headlines

BHC Price History

BHC Company Calendar

Last Earnings
8/02/2021
Today
6/02/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:BHC
CUSIP
N/A
CIK
885590
Web
www.bauschhealth.com
Phone
(514) 744-6792
Fax
514-744-6272
Employees
19,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.88
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+7.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.98)
Trailing P/E Ratio
N/A
Forward P/E Ratio
2.60
P/E Growth
0.13
Net Income
$-225,000,000.00
Net Margins
-4.38%
Pretax Margin
-2.25%
Return on Equity
381.67%
Return on Assets
3.94%

Debt

Debt-to-Equity Ratio
139.36
Current Ratio
1.08
Quick Ratio
0.77

Sales & Book Value

Annual Sales
$8.12 billion
Price / Sales
0.37
Cash Flow
$7.22 per share
Price / Cash Flow
1.14
Book Value
$0.40 per share
Price / Book
20.58

Miscellaneous

Outstanding Shares
362,040,000
Free Float
312,257,000
Market Cap
$2.98 billion
Optionable
Optionable
Beta
0.95

Key Executives

  • Thomas J. Appio
    Chief Executive Officer & Director
  • Mirza Dautbegovic
    Chief Operating Officer & Senior Vice President
  • Tom G. Vadaketh
    Chief Financial Officer & Executive Vice President
  • Tage Ramakrishna
    Chief Medical Officer, President-R&D
  • Seana-Lyn Carson
    Executive Vice President & General Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BHC Stock - Frequently Asked Questions

Should I buy or sell Bausch Health Companies stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares.
View BHC analyst ratings or view top-rated stocks.

What is Bausch Health Companies' stock price forecast for 2023?

4 Wall Street analysts have issued 1 year price objectives for Bausch Health Companies' stock. Their BHC share price forecasts range from $6.00 to $12.00. On average, they predict the company's share price to reach $8.88 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price.
View analysts price targets for BHC or view top-rated stocks among Wall Street analysts.

How have BHC shares performed in 2023?

Bausch Health Companies' stock was trading at $6.28 at the beginning of the year. Since then, BHC stock has increased by 31.1% and is now trading at $8.23.
View the best growth stocks for 2023 here.

Are investors shorting Bausch Health Companies?

Bausch Health Companies saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 23,350,000 shares, a decrease of 8.7% from the April 15th total of 25,580,000 shares. Based on an average trading volume of 4,300,000 shares, the short-interest ratio is presently 5.4 days. Approximately 6.6% of the company's stock are short sold.
View Bausch Health Companies' Short Interest.

When is Bausch Health Companies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our BHC earnings forecast.

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc. (NYSE:BHC) announced its earnings results on Monday, August, 2nd. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.95 by $0.02. The business earned $2.10 billion during the quarter, compared to the consensus estimate of $2.12 billion. Bausch Health Companies had a positive trailing twelve-month return on equity of 381.67% and a negative net margin of 4.38%.

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $8.35 billion-$8.55 billion, compared to the consensus revenue estimate of $8.35 billion.

What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO?

43 employees have rated Bausch Health Companies Chief Executive Officer Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among the company's employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC).

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (4.59%), Goldentree Asset Management LP (4.57%), National Bank of Canada FI (3.63%), Healthcare of Ontario Pension Plan Trust Fund (2.76%), ING Groep NV (2.08%) and Mizuho Markets Cayman LP (1.93%). Insiders that own company stock include Amy B Wechsler, Christina Ackermann, Holdings LP Valueact, Joseph F Gordon, Robert Spurr, Russell Barrans, Sam Eldessouky, Schutter Richard U De, Seana Carson, Steven D Miller and William D Humphries.
View institutional ownership trends.

How do I buy shares of Bausch Health Companies?

Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $8.23.

How much money does Bausch Health Companies make?

Bausch Health Companies (NYSE:BHC) has a market capitalization of $2.98 billion and generates $8.12 billion in revenue each year. The company earns $-225,000,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis.

How many employees does Bausch Health Companies have?

The company employs 19,900 workers across the globe.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The official website for the company is www.bauschhealth.com. The company can be reached via phone at (514) 744-6792, via email at ir@bauschhealth.com, or via fax at 514-744-6272.

This page (NYSE:BHC) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -